Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors
Renu Sehrawat, Ritu Pasrija, Priyanka Rathee, Deepika Kumari, Anurag Khatkar · 2024
Read Molecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors by Renu Sehrawat, Ritu Pasrija, Priyanka Rathee, Deepika Kumari, Anurag Khatkar (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11658390.txt.
Description
Renu Sehrawat and co-authors designed new drug candidates from caffeic acid, a plant compound, aimed at an enzyme that cancer and microbes both depend on. The enzyme, DHFR, drives the folate chemistry cells need to grow and divide; blocking it is the strategy behind the established drug methotrexate. The team modeled, synthesized, and tested a series of derivatives against the enzyme, bacteria, and breast cancer cells.
One compound, CE11, blocked DHFR about four times more strongly than methotrexate and docked into the same pocket. It also killed breast cancer cells at low doses. Two sibling compounds beat standard antibiotics against several bacteria, including resistant problem species. Computer docking explained the grip: snug fits in greasy pockets plus a few well-placed hydrogen bonds.
Catalog record
| CREATOR | Renu Sehrawat, Ritu Pasrija, Priyanka Rathee, Deepika Kumari, Anurag Khatkar |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |